Skip to main content

Advertisement

Advertisement

ADVERTISEMENT

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

An interview with Jeff P. Sharman, MD

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug Administration (FDA) approval of the chronic lymphocytic leukemia (CLL) indication for BRUKINSA® in January 2023.

 

Advertisement

Advertisement

Advertisement